On Friday, Glenmark Life Sciences said its profit after tax grew 11 per cent YoY to Rs 119 crore for the second quarter ended September 30, 2023.
During the quarter Revenue from operations rose by 17 per cent YoY to Rs 595 crore. Glenmark Life Sciences said in a regulatory filing.
“Geographically, regulated markets including the US, Europe, LATAM and India continue to spearhead our growth,” Glenmark Life Sciences MD and CEO Yasir Rawjee said.
LATAM refers to Latin American countries.
Looking ahead, enhanced visibility towards the H2 FY24 demand for generic API and CDMO business bolsters the company’s confidence in delivering growth in FY24, he added.
Shares of the company closed 0.34 per cent down at Rs 621.30 on the BSE.
